Dailypharm Live Search Close

BMS makes 2nd voluntary price cut for Baraclude this year

By Lee, Tak-Sun | translator Kim, Jung-Ju

23.07.21 12:10:53

°¡³ª´Ù¶ó 0
Voluntarily adjusts insurance ceiling price while listing new drug Onureg Tab

Made the first price cut when listing its new drug ¡®Inrebic Cap.¡¯


BMS Korea made the decision to carry out a second voluntary price cut on its flagship hepatitis B treatment ¡®Baraclude¡¯ this year.

It is rare for an original drug to undergo two voluntary price cuts in one year. The industry analysis is that the company is using the price cut of its off-patent drug Baraclude as leverage to list new drugs.

According to industry sources on the 21st, BMS Korea voluntarily reduced the insurance ceiling price for its 0.5mg dose Baraclude (entecavir) from KRW 3,030 to KRW 3,006, and its 1mg dose from KRW 3,430 to KRW 3,403, effective as of August 1st.

As a result, Baraclude¡¯s price is now placed in the mid-range among same ingredient drugs.

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)